EXTENSION OF COVERAGE OF INTRAVENOUS IMMUNE GLOBULIN (IVIG) FOR THE TREATMENT OF PRIMARY IMMUNE DEFICIENCY DISEASES IN THE HOME.

SEC. 642. EXTENSION OF COVERAGE OF INTRAVENOUS IMMUNE GLOBULIN (IVIG) FOR THE TREATMENT OF PRIMARY IMMUNE DEFICIENCY DISEASES IN THE HOME.(a) In General.—Section 1861 (42 U.S.C. 1395x), as amended by sections 611(a) and 612(a) is amended—(1) in subsection (s)(2)—(A) by striking “and” at the end of subparagraph (X);(B) by adding “and” at the end of subparagraph (Y); and (C) by adding at the end the following new subparagraph:“(Z) intravenous immune globulin for the treatment of primary immune deficiency diseases in the home (as defined in subsection (zz));”; and(2) by adding at the end the following new subsection:“Intravenous Immune Globulin“(zz) The term ‘intravenous immune globulin’ means an approved pooled plasma derivative for the treatment in the patient’s home of a patient with a diagnosed primary immune deficiency disease, but not including items or services related to the administration of the derivative, if a physician determines administration of the derivative in the patient’s home is medically appropriate.”.(b) Payment as a Drug or Biological.—Section 1833(a)(1)(S) (42 U.S.C. 1395l(a)(1)(S)) is amended by inserting “(including intravenous immune globulin (as defined in section 1861(zz)))” after “with respect to drugs and biologicals”.(c) Effective Date.—The amendments made by this section shall apply to items furnished administered on or after January 1, 2004.